Avita Medical (ASX:AVH) reported Friday a loss of $0.44 per diluted share in the fourth quarter of 2024, compared with a loss of $0.28 per diluted share in the same period in 2023.
Analysts polled by Visible Alpha also expected a loss of $0.44.
The dual-listed firm said the wider net loss was due to higher operating expenses and lower other income, net, partially offset by higher gross profit.
Total revenue in the quarter ended Dec. 31, 2024, came in at $18.4 million, compared with $14.2 million in the corresponding period in the prior year. Analysts polled by Visible Alpha expected $20.3 million.
The company said it expects its full-year 2025 commercial revenue to be in the range of $100 to $106 million, reflecting growth of approximately 55% to 65% over the full-year 2024.
The company's shares surged past 12% in recent Friday trade in Australia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.